Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03454035 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03454035 · ClinicalTrials.gov record · last posted 2026-08-19

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

StatusRecruiting
PhasePhase 1
Started2018-01-30
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined with the CDK4/6 inhibitor palbociclib.

Protocol amendment history 2 changes detected by DataLookout

2026-08-20
Primary completion pushed: 2026-07-15 → 2028-02-03
2026-08-20
Completion pushed: 2026-11-24 → 2028-02-03
Trial Details
NCT Number NCT03454035
Lead Sponsor UNC Lineberger Comprehensive Cancer Center
Collaborators: BioMed Valley Discoveries, Inc, Pfizer
Conditions Tumor, Solid, Pancreatic Cancer, Melanoma
Enrollment 45 participants
Start Date 2018-01-30
Primary Completion 2028-02-03 (estimated)
Study Completion 2028-02-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-19